Kringle Pharma

4884

Osaka, Japan· Est. 2001

Is this your company? Claim your profile to update info and connect with investors.

Overview

Late-stage biotech developing HGF protein therapies for intractable neurological and regenerative diseases, with lead program in acute spinal cord injury.

NeuroscienceRegenerative MedicineRare Diseases

Technology Platform

Proprietary manufacturing system for pharmaceutical-grade recombinant human Hepatocyte Growth Factor (HGF) protein, an endogenous regenerative factor with protective, anti-fibrotic, and tissue-repairing functions.

Opportunities

Potential first-in-class approval for acute spinal cord injury in Japan could validate the HGF platform and create opportunities for expansion into other fibrotic and degenerative diseases across multiple organ systems.

Risk Factors

High dependency on a single technology platform (HGF), limited financial and human resources (17 employees), and clinical development risks in challenging regenerative medicine indications with high unmet need.

Competitive Landscape

Competes in niche regenerative medicine spaces with companies developing neuroprotective agents, anti-fibrotics, and growth factor therapies; differentiation lies in specialized HGF manufacturing expertise and first-mover potential in acute SCI in Japan.